Ahmed E.M.Khalil N.A.Taher A.T.Refaey R.H.Nissan Y.M.Pharmaceutical Organic Chemistry DepartmentFaculty of PharmacyCairo UniversityCairoEgypt; Pharmaceutical Organic Chemistry DepartmentFaculty of PharmacyOctober 6 UniversityGizaEgypt; Pharmaceutical Chemistry DepartmentFaculty of PharmacyOctober University for Modern Sciences and Arts (MSA)GizaEgypt; Pharmaceutical Chemistry DepartmentFaculty of PharmacyCairo UniversityKasr Elini St.Cairo11562Egypt2020-01-092020-01-092019452068https://doi.org/10.1016/j.bioorg.2019.103272PubMed ID 31539742https://t.ly/AXqNpScopusNovel series of some triazolo[4,3-b]pyridazine derivatives were designed and synthesized. All the newly synthesized compounds were evaluated for their cytotoxic activity at 10?5 M concentration towards 60 cancer cell lines according to USA NCI protocol. Most of the synthesized compounds showed good activity against SR (leukemia) cell panel. The most active compounds, 2f and 4a were subjected for further evaluation at a five dose level screening and their efficacy for c-Met kinase inhibition was determined in vitro. Binding mode of these derivatives was explored via molecular docking. 2019 Elsevier Inc.Englishc-Met kinaseCytotoxic activityPyridazinesTriazolopyridazinescytotoxic agentphosphotransferase inhibitorscatter factor receptortriazolopyridazine derivativeantineoplastic activityArticlebreast cancercancer inhibitioncentral nervous system cancercolon cancercontrolled studydrug bindingdrug efficacydrug screeningdrug synthesisenzyme activityenzyme inhibitionGI50humanhuman cellIC50in vitro studykidney cancerleukemiamelanomamolecular dockingnon small cell lung cancerovary cancerpriority journalprostate cancerproton nuclear magnetic resonancestructure activity relationArticlehttps://doi.org/10.1016/j.bioorg.2019.103272PubMed ID 31539742